



See what you have to gain

Contact Us:

For more information about MultiHance, please contact Bracco Professional Services at 1-800-257-5181 Opt. 2 or email Bracco Customer Service at bracco.otc@diag.bracco.com.

Available in 5, 10, 15, and 20 mL single-dose vials, and 50 and 100 mL Multipack^{®*} (Pharmacy Bulk Packages)

Size	NDC Number
5 mL vials	0270-5164-12
10 mL vials	0270-5164-13
15 mL vials	0270-5164-14
20 mL vials	0270-5164-15
50 mL Multipack*	0270-5264-16
100 mL Multipack*	0270-5264-17



* Not for Direct Infusion.

Magnevist is a registered trademark of Bayer Healthcare Pharmaceuticals Inc.

MultiHance has a significantly greater relaxivity, and provides statistically significant ($p < 0.0001$) better contrast enhancement and diagnostic information in MRI of CNS lesions compared to Magnevist[®] (gadopentetate dimeglumine) at an equivalent dose.^{(1),(2)}

MultiHance (gadobenate dimeglumine) injection, 529 mg/mL is the first extracellular fluid (ECF) contrast agent to possess a weak and transient interaction with plasma proteins, a characteristic that endows MultiHance with up to twice the in vivo relaxivity of all other ECF contrast agents.⁽³⁾ This improved relaxation effect could potentially contribute to improved lesion visualization.

The MultiHance molecule, gadobenate, has a structure very similar to that of gadopentetate, except that MultiHance has a benzyloxymethyl group protruding from the molecule.⁽⁴⁾ This lipophilic structure provides MultiHance with the ability to weakly and reversibly interact with plasma proteins and also to be taken up by functioning hepatocytes. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL provides statistically significant ($p < 0.0001$) better contrast enhancement and diagnostic information in MRI of CNS lesions compared to Magnevist[®] (gadopentetate dimeglumine) at an equivalent dose.⁽⁵⁾

Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with:

- Acute or chronic severe renal insufficiency (glomerular filtration rate $< 30 \text{ mL/min/1.73m}^2$), or
- Acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent from the body prior to any readministration.

As with all paramagnetic agents, caution should be exercised in patients with deoxygenated sickle erythrocytes. The possibility of a reaction, including serious, life threatening, or fatal, anaphylactic or cardiovascular reactions, or other idiosyncratic reactions, should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic respiratory disorders.

For more information on MultiHance, visit www.multihanceUSA.com.

For more medical information, call Bracco Professional Services at 1-800-257-5181. Opt 2

For more information about Bracco products, visit www.bracco.com or call

Bracco Customer Service at 1-877-Bracco-9 (1-877-272-2269).

[1] Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. *Radiology* 2004; 230:55-64.
[2] Maravilla KR, Malsjian JA, Schmalzuss IM, et al. Contrast Enhancement of Central Nervous System Lesions: Multicenter Intraindividual Crossover Comparative Study of Two MR Contrast Agents. *Radiology* 2006; 240: 389-400.
[3] deHaen C, Cabrini M, Akhnana L, et al. Gadobenate Dimeglumine 0.5 M Solution for Injection (MultiHance ©): Pharmaceutical Formulation and Physicochemical Properties of a New Magnetic

Resonance Imaging Contrast Medium. *J Comput Assist Tomogr*; Vol. 23 (Suppl. 1), 1999.

[4] deHaen C, Cabrini M, Akhnana L, et al. Gadobenate Dimeglumine 0.5 M Solution for Injection (MultiHance ©): Pharmaceutical Formulation and Physicochemical Properties of a New Magnetic Resonance Imaging Contrast Medium. *J Comput Assist Tomogr*; Vol. 23 (Suppl. 1), 1999.

[5] Maravilla KR, Malsjian JA, Schmalzuss IM, et al. Contrast Enhancement of Central Nervous System Lesions: Multicenter Intraindividual Crossover Comparative Study of Two MR Contrast Agents. *Radiology* 2006; 240: 389-400